Clinical Trials Arena on MSN7d
J&J drops Phase III MDD programme due to lack of efficacy
J&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...
The American Journal of Managed Care2d
Contributor: The Role of Dynamic Pricing in Health Technology Assessment for MDD
Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.
Advanced computational models enhance understanding, diagnoses of neuropsychiatric and neurological diseases
Major depressive disorder (MDD) is a serious mental health condition that impacts individuals of all ages, including children ...
J&J to stop studies of depression drug due to low effectiveness
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
Fierce Biotech8d
J&J fails to ace Ventura, stopping phase 3 depression program over 'insufficient efficacy'
Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...
MPR4d
J&J Ends Phase 3 Program Evaluating Aticaprant for Depression
Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...
MassDevice4d
Sooma wins FDA IDE for neuromod tech that treats depression
Sooma announced that it received FDA investigational device exemption (IDE) for its transcranial direct current stimulation ...